Population pharmacokinetic analysis of vancomycin using serum cystatin C as a marker of renal function

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 2, 2010, Pages 778-782

  Tanaka, Akihiro ^a   Aiba, Tetsuya ^b   Otsuka, Takashi ^c   Suemaru, Katsuya ^a   Nishimiya, Tatsuya ^a   Inoue, Tomoyoshi ^c   Murase, Mitsuharu ^a   Kurosaki, Yuji ^b   Araki, Hiroaki ^a  

^a EHIME UNIVERSITY HOSPITAL   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c Matsuyama Shimin Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTATIN C; VANCOMYCIN;

ACCURACY; ADOLESCENT; ADULT; AGED; ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; CYSTATIN C BLOOD LEVEL; DATA ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; FUNCTIONAL ASSESSMENT; GLOMERULUS FILTRATION RATE; HUMAN; INTERRATER RELIABILITY; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PERFORMANCE MEASUREMENT SYSTEM; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CYSTATIN C; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FUNCTION TESTS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN; YOUNG ADULT;

EID: 75749128980     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00661-09     Document Type: Article

References (35)

1. Birt, J. K., and M. H. Chandler. 1990. Using clinical data to determine vancomycin dosing parameters. Ther. Drug Monit. 12:206-209.
2. Buelga, D. S., M. del Mar Fernandez de Gatta, E. V. Herrera, A. Dominguez-Gil, and M. J. García. 2005. Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies. Antimicrob. Agents Chemother. 49:4934-4941.
3. Cantu, T. G., N. A. Yamanaka-Yuen, and P. S. Lietman. 1994. Serum vancomycin concentrations: reappraisal of their clinical value. Clin. Infect. Dis. 18:533-543.
4. Cockcroft, D. W., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
5. Coll, E., A. Botey, L. Alvarez, E. Poch, L. Quintó, A. Saurina, M. Vera, C. Piera, and A. Darnell. 2000. Serum cystatin-C as a new marker for nonin-vasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am. J. Kidney Dis. 36:29-34.
6. Cunha, B. A. 1995. Vancomycin. Med. Clin. North Am. 79:817-831.
7. Dharnidharka, V. R., C. Kwon, and G. Stevens. 2002. Serum cystatin-C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am. J. Kidney Dis. 40:221-226.
8. DuBois, D., and E. F. DuBois. 1916. A formula to estimate the approximate surface area if height and weight are known. Arch. Intern. Med. 17:863-871.
9. Ducharme, M. P., R. L. Slaughter, and D. J. Edwards. 1994. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther. Drug Monit. 16:513-518.
10. Filler, G., A. Bokenkamp, W. Hofmann, T. Le Bricon, C. Martínez-Brú, and A. Grubb. 2005. Cystatin C as a marker of GFR-history, indications, and future research. Clin. Biochem. 38:1-8.
11. Finney, H., C. J. Bates, and C. P. Price. 1999. Plasma cystatin C determinations in a healthy elderly population. Arch. Gerontol. Geriatr. 29:75-94.
12. Golper, T. A., H. M. Noonan, L. Elzinga, D. Gilbert, R. Brummett, J. L. Anderson, and W. M. Bennett. 1988. Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects. Clin. Pharmacol. Ther. 43:565-570.
13. Hermida, J., and J. C. Tutor. 2006. Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin. Ther. Drug Monit. 28:326-331.
14. Hoek, F. J., F. A. Kemperman, and R. T. Krediet. 2003. A comparison between cystatin C plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol. Dial. Transplant. 18:2024-2031.
15. Hoppe, A., S. Seronie-Vivien, F. Thomas, J. P. Delord, L. Malard, P. Canal, and E. Chatelut. 2005. Serum cystatin C is a better marker of topotecan clearance than serum creatinine. Clin. Cancer Res. 11:3038-3044.
16. Iwamoto, T., Y. Kagawa, and M. Kojima. 2003. Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol. Pharm. Bull. 26:876-879.
17. Levey, A. S., R. L. Berg, J. J. Gassmann, P. M. Hall, and W. G. Walker. 1989. Creatinine filtration, secretion and excretion during progressive renal disease. Kidney Int. 36(Suppl. 27):S73-S80.
18. MacGowan, A. P. 1998. Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides. Ther. Drug Monit. 20:473-477.
19. Macias, W. L., B. A. Mueller, and S. K. Scarim. 1991. Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance. Clin. Pharmacol. Ther. 50:688-694.
20. Moise-Broder, P. A., A. Forrest, M. C. Birmingham, and J. J. Schentag. 2004. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin. Pharmacokinet. 43:925-942.
21. Moise-Border, P. A. 2006. Vancomycin, p. 328-340. In M. E. Burton, L. M. Shaw, J. J. Schentag, and W. E. Evans (ed.), Applied pharmacokinetics & pharmacodynamics 4th, ed. Lippincott Williams & Wilkins, Baltimore, MD.
22. NONMEM Project Group. 1992. In S. L. Beal and L. B. Sheiner (ed.), NONMEM users' guide. University of California at San Francisco, San Francisco, CA.
23. Okamoto, G., T. Sakamoto, M. Kimura, Y. Ukishima, A. Sonoda, N. Mori, Y. Kato, T. Maeda, and Y. Kagawa. 2007. Serum cystatin C as a better marker of vancomycin clearance than serum creatinine in elderly patients. Clin. Biochem. 40:485-490.
24. Pachorek, R. E., and F. Wood. 1991. Vancomycin half-life in a patient with hepatic and renal dysfunction. Clin. Pharm. 10:297-300.
25. Rodvold, K. A., R. D. Pryka, M. Garrison, and J. C. Rotschafer. 1989. Evaluation of a two-compartment Bayesian forecasting program for predicting vancomycin concentrations. Ther. Drug Monit. 11:269-275.
26. Rybak, M. J., and S. C. Boike. 1986. Monitoring vancomycin therapy. Drug Intell. Clin. Pharm. 20:757-761.
27. Rybak, M. J. 2006. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin. Infect. Dis. 42:S35-S39.
28. Rybak, M. J., L. M. Albrecht, S. C. Boike, and P. H. Chandrasekar. 1990. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J. Antimicrob. Chemother. 25:679-687.
29. Shalansky, S. 1995. Rationalization of vancomycin serum concentration monitoring. Can. J. Hosp. Pharm. 48:17-24.
30. Sheiner, L. B., and S. L. Beal. 1981. Some suggestions for measuring predictive performance. J. Pharmacokinet. Biopharm. 9:503-512.
31. Tanaka, A., K. Suemaru, T. Otsuka, K. Ido, T. Nishimiya, I. Sakai, H. Hasegawa, M. Yasukawa, T. Inoue, M. Murase, and H. Araki. 2007. Hoek's formula, a cystatin C-based prediction formula for determining the glomerular filtration rate, is the most effective method for original adjusting the dosage of vancomycin. Int. J. Clin. Pharmacol. Ther. 45:592-597.
32. Tanaka, A., K. Suemaru, T. Otsuka, K. Ido, T. Nishimiya, I. Sakai, H. Hasegawa, T. Inoue, M. Murase, M. Yasukawa, and H. Araki. 2007. Estimation of the initial dose setting of vancomycin therapy with use of cystatin C as a new marker of renal function. Ther. Drug Monit. 29:261-264.
33. Tanaka, A., K. Suemaru, and H. Araki. 2006. Evaluation of predictability for the initial dose setting of vancomycin by the population mean method. Jpn. J. Ther. Drug Monit. 23:221-522.
34. Wasen, E., R. Isoaho, K. Mattila, T. Vahlberg, S. L. Kivelä, and K. Irjala. 2004. Estimation of glomerular filtration rate in the elderly: a comparison of creatinine-based formulae with serum cystatin C. J. Intern. Med. 256:70-78.
35. Yasuhara, M., T. Iga, H. Zenda, K. Okumura, T. Oguma, Y. Yano, and R. Hori. 1998. Population pharmacokinetics of vancomycin in Japanese adult patients. Ther. Drug Monit. 20:139-148.